Standard BioTools, Inc. (LAB)
0.7146
+0.02
(+3.27%)
USD |
NASDAQ |
Sep 09, 11:24
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 280.21M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -49.12% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 3.266 |
| Price to Book Value | 0.5189 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.052 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 93.50% |
Profile
| Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA. |
| URL | http://www.standardbio.com |
| Investor Relations URL | https://investors.standardbio.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 03, 2026 (est.) |
| Last Earnings Release | Aug. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA. |
| URL | http://www.standardbio.com |
| Investor Relations URL | https://investors.standardbio.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap Core |
| Next Earnings Release | Nov. 03, 2026 (est.) |
| Last Earnings Release | Aug. 05, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |